FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021095717> ?p ?o ?g. }

• W2021095717 endingPage "e0125164" @default.
• W2021095717 startingPage "e0125164" @default.
• W2021095717 abstract "Background Few data are available regarding the use of antithrombotic strategies in coronary artery disease patients with atrial fibrillation (AF) in everyday practice. We sought to describe the prevalence of AF and its antithrombotic management in a contemporary population of patients with stable coronary artery disease. Methods and Findings CLARIFY is an international, prospective, longitudinal registry of outpatients with stable coronary artery disease, defined as prior (≥12 months) myocardial infarction, revascularization procedure, coronary stenosis >50%, or chest pain associated with evidence of myocardial ischemia. Overall, 33,428 patients were screened, of whom 32,954 had data available for analysis at baseline; of these 2,229 (6.7%) had a history of AF. Median (interquartile range) CHA2DS2-VASc score was 4 (3, 5). Oral anticoagulation alone was used in 25.7%, antiplatelet therapy alone in 52.8% (single 41.8%, dual 11.0%), and both in 21.5%. OAC use was independently associated with permanent AF (p<0.001), CHA2DS2-VASc score (p=0.006), pacemaker (p<0.001), stroke (p=0.04), absence of angina (p=0.004), decreased left ventricular ejection fraction (p<0.001), increased waist circumference (p=0.005), and longer history of coronary artery disease (p=0.008). History of percutaneous coronary intervention (p=0.004) and no/partial reimbursement for cardiovascular medication (p=0.01, p<0.001, respectively) were associated with reduced oral anticoagulant use. Conclusions In this contemporary cohort of patients with stable coronary artery disease and AF, most of whom are theoretical candidates for anticoagulation, oral anticoagulants were used in only 47.2%. Half of the patients received antiplatelet therapy alone and one-fifth received both antiplatelets and oral anticoagulants. Efforts are needed to improve adherence to guidelines in these patients. Trial Registration ISRCTN registry of clinical trials: ISRCTN43070564." @default.
• W2021095717 created "2016-06-24" @default.
• W2021095717 creator A5003831287 @default.
• W2021095717 creator A5007737202 @default.
• W2021095717 creator A5013502568 @default.
• W2021095717 creator A5016095791 @default.
• W2021095717 creator A5031309899 @default.
• W2021095717 creator A5047995526 @default.
• W2021095717 creator A5049309607 @default.
• W2021095717 creator A5059053820 @default.
• W2021095717 creator A5062655570 @default.
• W2021095717 date "2015-04-27" @default.
• W2021095717 modified "2023-10-13" @default.
• W2021095717 title "Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry" @default.
• W2021095717 cites W1475865131 @default.
• W2021095717 cites W1914259002 @default.
• W2021095717 cites W1947134634 @default.
• W2021095717 cites W1976469399 @default.
• W2021095717 cites W1987360574 @default.
• W2021095717 cites W2001420868 @default.
• W2021095717 cites W2005421130 @default.
• W2021095717 cites W2019712801 @default.
• W2021095717 cites W2030918284 @default.
• W2021095717 cites W2046271979 @default.
• W2021095717 cites W2050405051 @default.
• W2021095717 cites W2057308876 @default.
• W2021095717 cites W2087641863 @default.
• W2021095717 cites W2093858448 @default.
• W2021095717 cites W2121394112 @default.
• W2021095717 cites W2127985968 @default.
• W2021095717 cites W2138441387 @default.
• W2021095717 cites W2144582288 @default.
• W2021095717 cites W2144939065 @default.
• W2021095717 cites W2148352532 @default.
• W2021095717 cites W2150086052 @default.
• W2021095717 cites W2150646507 @default.
• W2021095717 cites W2159193915 @default.
• W2021095717 cites W2159370853 @default.
• W2021095717 cites W2160643867 @default.
• W2021095717 cites W2162586165 @default.
• W2021095717 cites W2164861810 @default.
• W2021095717 cites W2168210634 @default.
• W2021095717 cites W2171838412 @default.
• W2021095717 doi "https://doi.org/10.1371/journal.pone.0125164" @default.
• W2021095717 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4411156" @default.
• W2021095717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25915904" @default.
• W2021095717 hasPublicationYear "2015" @default.
• W2021095717 type Work @default.
• W2021095717 sameAs 2021095717 @default.
• W2021095717 citedByCount "11" @default.
• W2021095717 countsByYear W20210957172016 @default.
• W2021095717 countsByYear W20210957172017 @default.
• W2021095717 countsByYear W20210957172018 @default.
• W2021095717 countsByYear W20210957172019 @default.
• W2021095717 crossrefType "journal-article" @default.
• W2021095717 hasAuthorship W2021095717A5003831287 @default.
• W2021095717 hasAuthorship W2021095717A5007737202 @default.
• W2021095717 hasAuthorship W2021095717A5013502568 @default.
• W2021095717 hasAuthorship W2021095717A5016095791 @default.
• W2021095717 hasAuthorship W2021095717A5031309899 @default.
• W2021095717 hasAuthorship W2021095717A5047995526 @default.
• W2021095717 hasAuthorship W2021095717A5049309607 @default.
• W2021095717 hasAuthorship W2021095717A5059053820 @default.
• W2021095717 hasAuthorship W2021095717A5062655570 @default.
• W2021095717 hasBestOaLocation W20210957171 @default.
• W2021095717 hasConcept C119060515 @default.
• W2021095717 hasConcept C126322002 @default.
• W2021095717 hasConcept C127413603 @default.
• W2021095717 hasConcept C164705383 @default.
• W2021095717 hasConcept C2778198053 @default.
• W2021095717 hasConcept C2778213512 @default.
• W2021095717 hasConcept C2779161974 @default.
• W2021095717 hasConcept C2780400711 @default.
• W2021095717 hasConcept C2780645631 @default.
• W2021095717 hasConcept C2908647359 @default.
• W2021095717 hasConcept C500558357 @default.
• W2021095717 hasConcept C71924100 @default.
• W2021095717 hasConcept C78085059 @default.
• W2021095717 hasConcept C78519656 @default.
• W2021095717 hasConcept C99454951 @default.
• W2021095717 hasConceptScore W2021095717C119060515 @default.
• W2021095717 hasConceptScore W2021095717C126322002 @default.
• W2021095717 hasConceptScore W2021095717C127413603 @default.
• W2021095717 hasConceptScore W2021095717C164705383 @default.
• W2021095717 hasConceptScore W2021095717C2778198053 @default.
• W2021095717 hasConceptScore W2021095717C2778213512 @default.
• W2021095717 hasConceptScore W2021095717C2779161974 @default.
• W2021095717 hasConceptScore W2021095717C2780400711 @default.
• W2021095717 hasConceptScore W2021095717C2780645631 @default.
• W2021095717 hasConceptScore W2021095717C2908647359 @default.
• W2021095717 hasConceptScore W2021095717C500558357 @default.
• W2021095717 hasConceptScore W2021095717C71924100 @default.
• W2021095717 hasConceptScore W2021095717C78085059 @default.
• W2021095717 hasConceptScore W2021095717C78519656 @default.
• W2021095717 hasConceptScore W2021095717C99454951 @default.
• W2021095717 hasIssue "4" @default.
• W2021095717 hasLocation W20210957171 @default.
• W2021095717 hasLocation W202109571710 @default.

• next